2018
DOI: 10.1002/ijc.31820
|View full text |Cite
|
Sign up to set email alerts
|

Erratum: The efficacy and safety of anti‐PD‐1/PD‐L1 antibodies combined with chemotherapy or CTLA4 antibody as a first‐line treatment for advanced lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(5 citation statements)
references
References 3 publications
0
5
0
Order By: Relevance
“…76 However, given the reported outcomes were from studies with different sample size, inclusion of population with mixed treatment sequences and study designs, there is an apparent heterogeneity existing in this wide range of results and should be interpreted with caution. As for treatment-naive patients, median PFS was significantly better in patients receiving PD-1 plus chemotherapy than chemotherapy, 63 while no significantly prolonged OS was observed. Same results were shown from the global, phase III multicenter IMvigor130 trial.…”
Section: Discussionmentioning
confidence: 96%
See 3 more Smart Citations
“…76 However, given the reported outcomes were from studies with different sample size, inclusion of population with mixed treatment sequences and study designs, there is an apparent heterogeneity existing in this wide range of results and should be interpreted with caution. As for treatment-naive patients, median PFS was significantly better in patients receiving PD-1 plus chemotherapy than chemotherapy, 63 while no significantly prolonged OS was observed. Same results were shown from the global, phase III multicenter IMvigor130 trial.…”
Section: Discussionmentioning
confidence: 96%
“…OS of the immunotherapy plus chemotherapy group was not reached, while OS of the chemotherapy group was 17.8 months. 63 Two single-arm studies investigating tislelizumab and toripalimab demonstrated different efficacy profiles between PD-L1+ and PD-L1-subgroups. 15,61 In the first study, 113 patients with PD-L1+ UC who progressed during or following a platinum-based regimen were administered with tislelizumab.…”
Section: Immunotherapymentioning
confidence: 99%
See 2 more Smart Citations
“…At present, the first-line treatment regimen recommended by domestic and foreign guidelines is combined chemotherapy based on irinotecan; after the failure of first-line treatment, second-line treatment options can be selected, including fluorouracil, platinum-based chemotherapy, and immunotherapy. However, immunotherapy is a new tumor treatment method, and its effective rate is only about 5%-20% [1][2][3][4][5][6] . Therefore, finding more effective, safer, and tolerable immunotherapy is still an urgent problem to be solved.…”
Section: Introductionmentioning
confidence: 99%